October 09, 2015. CINCINNATI(BUSINESS WIRE)Aerpio Therapeutics, Inc a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced that data from the TIME-2 Phase 2a Study of AKB-9778 in the treatment of patients with diabetic macular edema (DME) will be presented at the upcoming American Academy of Ophthalmology (AAO) Annual Meeting’s Retina Subspecialty Day.